Outcomes and factors contributing to poor prognosis of Pneumocystis jirovecii pneumonia in HIV-negative patients: a cross-sectional retrospective study in a Chinese single center

被引：0

作者：

Ju Zhang

Xingcheng Sun

Jian Xu

Xiaodan Gu

Qian Chen

Jie Gao

Xia Xu

Ti Zhang

机构：

[1] Changhai Hospital,Department of Rheumatology and Immunology

[2] Second Military Medical University,Department of Emergency Medicine

[3] Changhai Hospital,National Clinical Research Center of Kidney Diseases

[4] Second Military Medical University,undefined

[5] Changhai Hospital,undefined

[6] Second Military Medical University,undefined

[7] Jinling Hospital,undefined

[8] Nanjing University School of Medicine,undefined

来源：

European Journal of Clinical Microbiology & Infectious Diseases | 2023年 / 42卷

关键词：

Immunocompromised patients; Pneumocystis jirovecii pneumonia; Prognosis; Risk factor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection mainly occurring in immunocompromised patients. Almost half of the 30 HIV-negative patients enrolled in this study from 2016–2020 in a Chinese single-center contracted 17 hematological malignancies, and 25 received long-term systemic corticosteroids. Only 4 patients received prophylaxis. The overall mortality was 30%. Patients with older age (> 43 years), dyspnea, and LDH > 404U/L had significantly higher risk of developing into a severe form. LDH > 424 U/L, PaO2 < 60 mmHg, monocyte < 0.2 × 10^9/L, and lymphocyte < 0.3 × 10^9/L were factors contributing to a poor survival outcome.

引用

页码：109 / 112

页数：3

共 22 条

[1]

Weyant RB(2021)Pneumocystis jirovecii: a review with a focus on prevention and treatment Expert Opin Pharmacother 22 1579-1592

[2]

Bateman M(2020)Diagnosing Pneumocystis jirovecii pneumonia: a review of current methods and novel approaches Med Mycol 58 1015-1028

[3]

Oladele R(2019)Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases Med Clin (Barc) 152 502-507

[4]

Kolls JK(2018)Pneumocystis jirovecii pneumonia in AIDS and non-AIDS immunocompromised patients - an update J Infect Dev Ctries 12 824-834

[5]

Braga BP(2021)On the treatment of pneumocystis jirovecii pneumonia: current practice based on outdated evidence Open Forum Infect Dis 8 ofab545-95

[6]

Prieto-Gonzalez S(2020)Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies Ann Intensive Care 10 34-65

[7]

Hernandez-Rodriguez J(2020)Lower mortality associated with adjuvant corticosteroid therapy in non-HIV-infected patients With Pneumocystis jirovecii pneumonia: a single-institution retrospective US cohort study Open Forum Infect Dis 7 ofaa354-2314

[8]

Lee YT(2014)Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection J Infect 69 88-undefined

[9]

Chuang ML(2018)Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia Respiration 96 52-undefined

[10]

McDonald EG(2021)Risk factors of mortality from Pneumocystis pneumonia in non-HIV patients: a meta-analysis Front Public Health 9 680108-undefined

← 1 2 3 →